SearchMenu

Engaging with healthcare professionals

GSK is committed to disclosing the payments we make, as we work together with healthcare professionals.

 

 

Photo of young woman

Global speaker programmes

For patients to benefit from new medical innovations, HCPs need to access and understand the latest available data and clinical use of the product.

Feedback from HCPs shows that they prefer to learn about new data and clinical experience through peer-to-peer programmes with global expert practitioners who have direct experience with our medicines. 

To help HCPs share new data on our products and understand their clinical use, in some cases we:

  • make fair market value payments to global expert practitioners who speak about the new science behind selected GSK products, their associated diseases and clinical practice in promotional settings
  • pay reasonable travel costs (except in the US) for an HCP to attend a GSK-organised standalone meeting to learn about data and clinical expertise.
  • directly pay registration fees for HCPs to attend remote congress webinars/webcasts. We do not sponsor HCPs to attend local and international conferences.

This policy is limited to select products in certain countries around the world and controls and training are in place, including measures to track appropriate payment and use of external speakers.

Where legally permitted, we will report individual-level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments. 

Collaborating on clinical trials and research 

Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results.

All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment.

We have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research.

Disclosure reports

  1. Outside of Europe and the US, we continue to support transparency as industry associations or governments establish specific guidelines for disclosure. Where legally permitted, we disclose annually individual level payments for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards in the markets where these activities take place. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.

  2. In the US, we report our payments and other transfers of value to US Healthcare Professionals and US Healthcare Organisations we have worked with, in compliance with federal and state transparency laws.  View the Federal CMS Open Payments data

  3. In Europe, we fully support and continue to implement the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to HCPs and HCOs. To affirm our commitment to the principles of the EFPIA Code of Practice we've signed this self-certification letter (PDF - 197KB). 

_